Dare Bioscience Inc (DARE)
0.4498
+0.01
(+3.31%)
USD |
NASDAQ |
Jun 14, 16:00
0.4272
-0.02
(-5.02%)
After-Hours: 20:00
Dare Bioscience Enterprise Value: 41.84M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 41.84M |
| June 13, 2024 | 40.39M |
| June 12, 2024 | 40.95M |
| June 11, 2024 | 43.24M |
| June 10, 2024 | 44.90M |
| June 07, 2024 | 48.94M |
| June 06, 2024 | 40.68M |
| June 05, 2024 | 39.72M |
| June 04, 2024 | 39.36M |
| June 03, 2024 | 37.82M |
| May 31, 2024 | 37.82M |
| May 30, 2024 | 39.90M |
| May 29, 2024 | 43.88M |
| May 28, 2024 | 37.63M |
| May 24, 2024 | 40.45M |
| May 23, 2024 | 42.33M |
| May 22, 2024 | 36.81M |
| May 21, 2024 | 39.27M |
| May 20, 2024 | 58.04M |
| May 17, 2024 | 45.43M |
| May 16, 2024 | 40.32M |
| May 15, 2024 | 32.76M |
| May 14, 2024 | 28.21M |
| May 13, 2024 | 28.23M |
| May 10, 2024 | 27.60M |
| Date | Value |
|---|---|
| May 09, 2024 | 27.91M |
| May 08, 2024 | 27.26M |
| May 07, 2024 | 27.55M |
| May 06, 2024 | 27.15M |
| May 03, 2024 | 27.67M |
| May 02, 2024 | 27.75M |
| May 01, 2024 | 29.55M |
| April 30, 2024 | 27.30M |
| April 29, 2024 | 24.72M |
| April 26, 2024 | 27.14M |
| April 25, 2024 | 25.46M |
| April 24, 2024 | 25.14M |
| April 23, 2024 | 26.27M |
| April 22, 2024 | 26.07M |
| April 19, 2024 | 24.53M |
| April 18, 2024 | 26.05M |
| April 17, 2024 | 24.80M |
| April 16, 2024 | 45.14M |
| April 15, 2024 | 44.66M |
| April 12, 2024 | 43.58M |
| April 11, 2024 | 44.85M |
| April 10, 2024 | 44.51M |
| April 09, 2024 | 43.74M |
| April 08, 2024 | 46.59M |
| April 05, 2024 | 45.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.754M
Minimum
Aug 07 2019
123.77M
Maximum
Jan 03 2022
48.11M
Average
45.50M
Median
Nov 24 2020
Enterprise Value Benchmarks
| Altimmune Inc | 251.19M |
| Verastem Inc | 39.95M |
| Oragenics Inc | 6.996M |
| Actinium Pharmaceuticals Inc | 148.85M |
| Orgenesis Inc | 46.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.755M |
| Revenue (Quarterly) | 0.0093M |
| Total Expenses (Quarterly) | 6.032M |
| EPS Diluted (Quarterly) | -0.07 |
| Profit Margin (Quarterly) | -72.62K% |
| Earnings Yield | -71.14% |
| Normalized Earnings Yield | -71.14 |